BPC-157 Reverses Doxorubicin-Induced Heart Failure and Big Endothelin-1 Elevation in Rats
BPC-157 reversed doxorubicin-induced congestive heart failure and reduced the associated Big Endothelin-1 elevation in rats, demonstrating cardioprotective effects against chemotherapy-induced cardiac damage.
Quick Facts
What This Study Found
BPC-157 reversed doxorubicin-induced CHF signs and normalized elevated Big Endothelin-1 levels in rats, comparable to amlodipine and losartan — demonstrating cardioprotective peptide activity against chemotherapy-induced cardiomyopathy.
Key Numbers
How They Did This
animal-study study on bpc-157, cardiovascular.
Why This Research Matters
Relevant for bpc-157, cardiovascular, inflammation.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding BPC-157 reversed doxorubicin-induced CHF signs and normalized elevated Big Endothelin-1 levels in rats, comparable to amlodipine and losartan — demons
- Evidence Grade:
- preliminary evidence.
- Study Age:
- Published in 2004.
- Original Title:
- Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.
- Published In:
- Journal of pharmacological sciences, 95(1), 19-26 (2004)
- Authors:
- Lovric-Bencic, Martina(2), Sikiric, Predrag(44), Hanzevacki, Jadranka S, Seiwerth, Sven, Rogic, Dunja, Kusec, Vesna, Aralica, Gorana, Konjevoda, Pasko, Batelja, Lovorka, Blagaic, Alenka B
- Database ID:
- RPEP-00944
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
BPC-157 Reverses Doxorubicin-Induced Heart Failure and Big Endothelin-1 Elevation in Rats
What was found?
BPC-157 reversed doxorubicin-induced congestive heart failure and reduced the associated Big Endothelin-1 elevation in rats, demonstrating cardioprotective effects against chemotherapy-induced cardiac damage.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00944APA
Lovric-Bencic, Martina; Sikiric, Predrag; Hanzevacki, Jadranka S; Seiwerth, Sven; Rogic, Dunja; Kusec, Vesna; Aralica, Gorana; Konjevoda, Pasko; Batelja, Lovorka; Blagaic, Alenka B. (2004). Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.. Journal of pharmacological sciences, 95(1), 19-26.
MLA
Lovric-Bencic, Martina, et al. "Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.." Journal of pharmacological sciences, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Doxorubicine-congestive heart failure-increased big endothel..." RPEP-00944. Retrieved from https://rethinkpeptides.com/research/lovric-bencic-2004-doxorubicinecongestive-heart-failureincreased-big
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.